Neurocrine Biosciences (NASDAQ:NBIX) Stock: Insider George Morrow Sells 300 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 300 shares of the stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $149.00, for a total transaction of $44,700.00. Following the completion of the transaction, the director directly owned 10,386 shares of the company’s stock, valued at approximately $1,547,514. The trade was a 2.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Trading Up 0.7%

NBIX opened at $166.05 on Thursday. The stock has a 50-day moving average of $146.98 and a 200 day moving average of $147.77. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The firm has a market cap of $16.81 billion, a P/E ratio of 24.64, a P/E/G ratio of 0.73 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business posted $2.04 earnings per share. The company’s quarterly revenue was up 41.3% compared to the same quarter last year. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 7.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of NBIX. Keybank National Association OH grew its holdings in Neurocrine Biosciences by 4.7% during the 3rd quarter. Keybank National Association OH now owns 2,001 shares of the company’s stock worth $284,000 after acquiring an additional 89 shares in the last quarter. New York Life Investment Management LLC increased its position in Neurocrine Biosciences by 17.1% during the 3rd quarter. New York Life Investment Management LLC now owns 17,375 shares of the company’s stock valued at $2,464,000 after purchasing an additional 2,543 shares during the period. M&G PLC raised its holdings in shares of Neurocrine Biosciences by 1.2% in the 3rd quarter. M&G PLC now owns 89,345 shares of the company’s stock valued at $12,687,000 after purchasing an additional 1,084 shares in the last quarter. AlphaCore Capital LLC raised its holdings in shares of Neurocrine Biosciences by 11.3% in the 3rd quarter. AlphaCore Capital LLC now owns 4,698 shares of the company’s stock valued at $666,000 after purchasing an additional 478 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its position in shares of Neurocrine Biosciences by 0.8% in the 3rd quarter. Retirement Systems of Alabama now owns 104,845 shares of the company’s stock worth $14,871,000 after purchasing an additional 848 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on NBIX shares. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Royal Bank Of Canada lifted their price objective on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stifel Nicolaus boosted their price objective on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Needham & Company LLC reissued a “buy” rating and issued a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. Finally, Truist Financial increased their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $202.32.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported Q3 revenue of $1.12 billion, up 41% year over year and above expectations, with EPS of $3.29 also beating estimates. The company raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion, reflecting product demand and supporting the growth outlook. Q3 results and updated sales outlook
• Positive Sentiment: Guggenheim raised its price target to $224 from $207 and maintained a Buy rating. Canaccord, Piper Sandler and RBC also lifted their targets after the results, adding to a broadly favorable analyst response.
• Neutral Sentiment: The company has started a Phase 2 Alzheimer’s study, offering a potential longer-term pipeline opportunity, but the supplied report provides few details on the study or its prospects. Alzheimer’s study update
• Negative Sentiment: Director George J. Morrow reported selling shares in multiple transactions, including sales on November 2 and 3. The filings indicate the trades were made under a pre-arranged Rule 10b5-1 plan, which may lessen the significance, but insider selling can still concern investors.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, which could affect how much value the company ultimately captures from the deal. Soleno acquisition risks

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.